



Hybio Pharmaceutical (Wuhan) Co.,Ltd.
Certificate of Analysis

DE202412-033

QC2-P12-01

Product Name	Tirzepatide	Batch Number	0422401A
Manufacture Date	Sept.26,2024	Delivery Quantity	5g
Test Date	Oct.08, 2024	Report Date	Dec.17, 2024
Retest Date	Sept.25,2026	Storage	Store under -20±5℃ without direct sunlight after sealing
Test Standard	2-TSF-0052 Tirzepatide quality specification (Version 2.0)		
Test Item	Specification	Result	
[Character]			
Appearance	White or off-white powder or loose lump	White powder	
Hygroscopicity	Has hygroscopic properties,with a hygroscopic weight gain of less than 15% but not less than 2%	Conform(11%)	
Solubility	Freely soluble in water.almost insoluble or insoluble in acetonitrile	Conform	
Specific optical rotation	-25°~-35°(calculated with reference to the anhydrous and sodium ion-free)	-29°	
[Identification]			
HPLC	The RT of the main peak of sample in the assay test should be consistent with that of the reference.	Conform	
MS	The monoisotopic molecular weight of the sample should be 4810.5±0.5Da	4810.5Da	
Peptide mapping	The retention time of characteristic peaks P1 to P5 in the chromatogram of the sample solution is consistent with the retention time of the reference solution	Conform	
[Check]			
pH	6.0~8.5	6.2	
Water content	≤10.0%	2.0%	
Clarity and color of solution	The solution is colorless and clear	conform	
Sodium ion	≤3.0%	0.9%	

Add: No.9, Linkong West Street, Hengdian Street, Huangpi District, Wuhan City, China

Tel: +86-27-59300199

Web: www.hybio.com.cn



Hybio Pharmaceutical (Wuhan) Co.,Ltd.

Certificate of Analysis

DE202412-033

QC2-P12-01

Product Name	Tirzepatide	Batch Number	0422401A
Test Standard	2-TSF-0052 Tirzepatide quality specification (Version 2.0)		
Test Item	Specification	Result	
Amino acid analysis	Asp: 1.8~2.2	2.1	
	Ser: 4.0~5.0	4.2	
	Glu: 3.6~4.4	4.1	
	Gly: 3.6~4.4	3.9	
	Thr: 1.5~2.2	1.8	
	Ala: 3.6~4.4	4.0	
	Pro: 3.6~4.4	4.1	
	Tyr: 1.8~2.2	1.9	
	Aib: 1.8~2.2	1.9	
	Lys: 1.8~2.2	2.2	
	Val: 0.9~1.1	1.0	
	Ile: 2.7~3.3	3.0	
	Leu: 1.8~2.2	2.0	
	Phe: 1.8~2.2	1.9	
Related substance	Method I		
	Impurity A $\leq$ 0.15%	0.10%	
	Method II		
	Impurity B $\leq$ 0.12%	0.04%	
	Impurities at position C and D(Deduction Method III impurity C and Impurity D) $<$ 0.10%	0.03%	
	Impurities at position E(Deduction Method III impurity E) $<$ 0.10%	0.05%	
	Impurity G $<$ 0.15%	0.04%	
	Impurities at position H(Deduction Method III impurity H) $<$ 0.20%	0.02%	
	Impurity I $\leq$ 0.20%	0.11%	
	Impurity J $\leq$ 0.20%	N.D	
	Other single impurity $<$ 0.20%	0.07%	
	Total impurities(Impurity A in method D) $\leq$ 2.0%	0.87%	
	Method III		
	Impurity C $<$ 0.10%	0.02%	
	Impurity D $<$ 0.10%	0.01%	
	Impurity E $<$ 0.10%	0.03%	
	Impurity H $<$ 0.13%	0.09%	

Add: No.9, Linkong West Street, Hengdian Street, Huangpi District, Wuhan City, China

Tel: +86-27-59300199

Web: www.hybio.com.cn



Hybio Pharmaceutical (Wuhan) Co.,Ltd.
Certificate of Analysis

DE202412-033

QC2-P12-01

Product Name		Tirzepatide	Batch Number	0422401A
Test Standard		2-TSF-0052 Tirzepatide quality specification (Version 2.0)		
Test Item		Specification		Result
Polymer impurities		≤0.20%		0.04%
Residual solvent		Methanol: ≤3000ppm Acetonitrile: ≤410ppm		25ppm 336ppm
Bacterial endotoxins		<5EU/mg		<2.5EU/mg
Microbial limits		TAMC: ≤2×10²cfu/g TYMC: ≤5×10¹cfu/g		TAMC: <1×10cfu/g TYMC: <1×10cfu/g
[Assay]				
Assay		95.0%~105.0% (calculated with reference to the anhydrous and sodium)		101.9%
		No content below		
Conclusion		Tests were performed according to 2-TSF-0052 Tirzepatide quality specification (Version 2.0), the results conform with specification.		
Remark		R&D only.		
Reporter		Ming Yang	Date	Dec. 17, 2024
Reviewer		Qi Fang	Date	Dec. 17, 2024

Add: No.9, Linkong West Street, Hengdian Street, Huangpi District, Wuhan City, China

Tel: +86-27-59300199

Web: www.hybio.com.cn